Chemical entities are capable of inducing the degradation of the cellular prion protein (PrP.sup.C) identified with the pharmacological protein inactivation by folded intermediate targeting (PPI-FIT) methodology.

Chemical entities are capable of inducing the degradation of the cellular prion protein (PrP.sup.C) identified with the pharmacological protein inactivation by folded intermediate targeting (PPI-FIT) methodology.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

The present application relates generally to methods for treating glioblastoma, or glioblastoma multiforme (GBM), with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, or the pharmaceutically acceptable salt thereof.

The present application relates generally to methods for treating glioblastoma, or glioblastoma multiforme (GBM), with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, or the pharmaceutically acceptable salt thereof.

The present application relates generally to methods for treating glioblastoma, or glioblastoma multiforme (GBM), with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one, or the pharmaceutically acceptable salt thereof.

Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: ##STR00001##
wherein values for the variables (e.g., Ring A, L, R.sup.1, R.sup.2, R.sup.3, m) are as described herein.

Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: ##STR00001##
wherein values for the variables (e.g., Ring A, L, R.sup.1, R.sup.2, R.sup.3, m) are as described herein.

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one LINE 1 (L-1) endonuclease inhibitor.